<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20221020056249N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-11</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of day and night splints in patients with CTS(carpal tunnel syndrome)</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of carpal tunnel injection of corticosteroids and night splints, with daily splints in patients with carpal tunnel syndrome according to changes in the degree of symptoms based on assessment forms and electrodiagnostic study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67166</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random allocation method in this study will be permutation block method. A represents a person who receives corticosteroid injections and daily splints, and B represents a person who receives corticosteroid injections and nightly splints.
This method is based on blocks of four so that the total number of possible permutations of four is equal to 6: BAAB ABBA , BBAA ،AABB ،BABA ،ABAB
Then, by using the table of random numbers and assigning a code from 0 to 9 to each of the permutations, the desired random list of 60 which includes 15 blocks of 4 is generated (using a computer) and the order of assigning each of the methods to Each of the samples participating in the study It is determined.
In order to hide ,the random sequence method is used by another person who is unaware of the research process , and the questionnaires are completed by a person who is unaware of the division of groups, Blinding description: Outcome assessor: Completed questionnaires and EDX findings are given to a person who is not aware of the interventions performed, and he is asked to rate the amount of pain reduction and increase in function and changes in nerve conduction velocity and latency according to the questionnaire and EDX findings.
Data analyst: Finally, after completing and collecting all the information, the questionnaires are given to a person to check the information, who does not know about any of the work steps and how the intervention is divided.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal Tunnel Syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a daily splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded. Intervention 2: Intervention group2: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a nightly splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All collected deidentified IPD

When:
Starting 6 months after publication

To whom:
Academic institutions

Conditions:
Practitoiners working in the same fields and who have CTS  patients.

Where to obtain:
Shiraz medical science university

How to obtain:
By making a request to the university

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Forouzan Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz Medical University of Science, Zand Ave., Shiraz Town.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134814336</zip>
        <telephone>+98 71 3630 5123</telephone>
        <email>Akbari.forouzan@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Forouzan Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz medical university,In front of Palestine St., Zand Ave., Shiraz Town.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134814336</zip>
        <telephone>+98 71 3230 5410</telephone>
        <email>akbari.forouzan@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>25-64 y/o
Patients diagnosed with mild to moderate CTS in electrodiagnostic study.</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Diabetes Melitus
Hypothyroidism
Inflammatory Arthropathy
Rheumatoid Arthritis
Polyneuropathy
Alcoholism
Infections
Cervical disc pathologies
History of past trauma or surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a daily splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded.</i_keyword>
      <i_keyword>Intervention group2: Injection of 40 mg of methylprednisolone is done in an area slightly proximal to the distal fold of the wrist between the palmaris longus and flexor carpi radialis tendons at the volar level of the wrist. Then a nightly splint will be prescribed and also at the beginning of the study and after 6 weeks, the severity of symptoms will be determined based on the VAS and Boston questionnaires, and the subjects will be subjected to electrodiagnosis and the relevant information will be recorded.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>VAS (visual analog scale) index for pain evaluation. Timepoint: At first and after 6 weeks of splint. Method of measurement: VAS questionaire.</prim_outcome>
      <prim_outcome>BCTSQ(Boston Carpal Tunnel Questionnaire) index for function evaluation. Timepoint: At first and after 6 weeks of splint. Method of measurement: Boston questionaire.</prim_outcome>
      <prim_outcome>NCV(nerve conduction velocity) and median nerve Latency in EDX( electrodiagnostic study). Timepoint: At first and after 6 weeks of splint. Method of measurement: Electrodiagnostic study.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-10-08</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>The central building of Shiraz University of Medical Sciences,across the Felestin Ave., Zand Ave.,Shiraz. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
